Skip to main
TRML
TRML logo

TRML Stock Forecast & Price Target

TRML Analyst Ratings

Based on 10 analyst ratings
Hold
Strong Buy 0%
Buy 10%
Hold 90%
Sell 0%
Strong Sell 0%

Bulls say

Tourmaline Bio Inc is experiencing a positive outlook due to significant clinical data demonstrating that its product candidate, pacibekitug, can achieve up to an 86% reduction in high-sensitivity C-reactive protein (hs-CRP) levels among patients with chronic kidney disease, showcasing its potential in treating autoimmune and inflammatory disorders. The company's strategic move to be acquired by Novartis aligns with the growing interest in IL-6-targeting therapies and emphasizes the importance of cardiovascular disease treatment, which could enhance Tourmaline's market presence. Furthermore, results from the Phase II TRANQUILITY study indicate robust, durable responses to pacibekitug dosing, paving the way for advancement into pivotal trials and bolstering investor confidence in its growth potential.

Bears say

Tourmaline Bio Inc is facing significant downside risks that could negatively impact its stock outlook, primarily centered around uncertainties related to a pending acquisition agreement with NVS, which may not materialize. Additionally, there are potential delays in commencing Phase II trials for its product candidate, pacibekitug, exacerbated by competitive pressures from other therapies targeting similar conditions. The company’s reliance on future financing until it achieves cash flow positivity also presents a considerable risk, as it may need to access capital markets under potentially unfavorable conditions.

TRML has been analyzed by 10 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 10% recommend Buy, 90% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tourmaline Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tourmaline Bio Inc (TRML) Forecast

Analysts have given TRML a Hold based on their latest research and market trends.

According to 10 analysts, TRML has a Hold consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $45.65, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $45.65, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tourmaline Bio Inc (TRML)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.